177 related articles for article (PubMed ID: 21775477)
1. Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor.
Lummis SC; Thompson AJ; Bencherif M; Lester HA
J Pharmacol Exp Ther; 2011 Oct; 339(1):125-31. PubMed ID: 21775477
[TBL] [Abstract][Full Text] [Related]
2. Differential modulation of brain nicotinic acetylcholine receptor function by cytisine, varenicline, and two novel bispidine compounds: emergent properties of a hybrid molecule.
Peng C; Stokes C; Mineur YS; Picciotto MR; Tian C; Eibl C; Tomassoli I; Guendisch D; Papke RL
J Pharmacol Exp Ther; 2013 Nov; 347(2):424-37. PubMed ID: 23959137
[TBL] [Abstract][Full Text] [Related]
3. Varenicline Interactions at the 5-HT3 Receptor Ligand Binding Site are Revealed by 5-HTBP.
Price KL; Lillestol RK; Ulens C; Lummis SC
ACS Chem Neurosci; 2015 Jul; 6(7):1151-7. PubMed ID: 25648658
[TBL] [Abstract][Full Text] [Related]
4. Varenicline is a partial agonist at alpha4beta2 and a full agonist at alpha7 neuronal nicotinic receptors.
Mihalak KB; Carroll FI; Luetje CW
Mol Pharmacol; 2006 Sep; 70(3):801-5. PubMed ID: 16766716
[TBL] [Abstract][Full Text] [Related]
5. A single channel mutation alters agonist efficacy at 5-HT3A and 5-HT3AB receptors.
Thompson AJ; Lummis SC
Br J Pharmacol; 2013 Sep; 170(2):391-402. PubMed ID: 23822584
[TBL] [Abstract][Full Text] [Related]
6. An unusual pattern of ligand-receptor interactions for the α7 nicotinic acetylcholine receptor, with implications for the binding of varenicline.
Van Arnam EB; Blythe EE; Lester HA; Dougherty DA
Mol Pharmacol; 2013 Aug; 84(2):201-7. PubMed ID: 23680636
[TBL] [Abstract][Full Text] [Related]
7. Pharmacological profile of the alpha4beta2 nicotinic acetylcholine receptor partial agonist varenicline, an effective smoking cessation aid.
Rollema H; Chambers LK; Coe JW; Glowa J; Hurst RS; Lebel LA; Lu Y; Mansbach RS; Mather RJ; Rovetti CC; Sands SB; Schaeffer E; Schulz DW; Tingley FD; Williams KE
Neuropharmacology; 2007 Mar; 52(3):985-94. PubMed ID: 17157884
[TBL] [Abstract][Full Text] [Related]
8. VUF10166, a novel compound with differing activities at 5-HT₃A and 5-HT₃AB receptors.
Thompson AJ; Verheij MH; de Esch IJ; Lummis SC
J Pharmacol Exp Ther; 2012 May; 341(2):350-9. PubMed ID: 22306960
[TBL] [Abstract][Full Text] [Related]
9. Electrophysiological perspectives on the therapeutic use of nicotinic acetylcholine receptor partial agonists.
Papke RL; Trocmé-Thibierge C; Guendisch D; Al Rubaiy SA; Bloom SA
J Pharmacol Exp Ther; 2011 May; 337(2):367-79. PubMed ID: 21285282
[TBL] [Abstract][Full Text] [Related]
10. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
Coe JW; Brooks PR; Vetelino MG; Wirtz MC; Arnold EP; Huang J; Sands SB; Davis TI; Lebel LA; Fox CB; Shrikhande A; Heym JH; Schaeffer E; Rollema H; Lu Y; Mansbach RS; Chambers LK; Rovetti CC; Schulz DW; Tingley FD; O'Neill BT
J Med Chem; 2005 May; 48(10):3474-7. PubMed ID: 15887955
[TBL] [Abstract][Full Text] [Related]
11. Molecular actions of smoking cessation drugs at α4β2 nicotinic receptors defined in crystal structures of a homologous binding protein.
Billen B; Spurny R; Brams M; van Elk R; Valera-Kummer S; Yakel JL; Voets T; Bertrand D; Smit AB; Ulens C
Proc Natl Acad Sci U S A; 2012 Jun; 109(23):9173-8. PubMed ID: 22619328
[TBL] [Abstract][Full Text] [Related]
12. Varenicline blocks β2*-nAChR-mediated response and activates β4*-nAChR-mediated responses in mice in vivo.
Ortiz NC; O'Neill HC; Marks MJ; Grady SR
Nicotine Tob Res; 2012 Jun; 14(6):711-9. PubMed ID: 22241831
[TBL] [Abstract][Full Text] [Related]
13. Use of an α3β4 nicotinic acetylcholine receptor subunit concatamer to characterize ganglionic receptor subtypes with specific subunit composition reveals species-specific pharmacologic properties.
Stokes C; Papke RL
Neuropharmacology; 2012 Sep; 63(4):538-46. PubMed ID: 22580377
[TBL] [Abstract][Full Text] [Related]
14. The effects of varenicline on sensory gating and exploratory behavior with pretreatment with nicotinic or 5-HT3A receptor antagonists.
Kucinski A; Wersinger S; Stachowiak EK; Becker C; Lippiello P; Bencherif M; Stachowiak MK
Behav Pharmacol; 2015 Feb; 26(1-2):217-26. PubMed ID: 25485645
[TBL] [Abstract][Full Text] [Related]
15. Activation and inhibition of mouse muscle and neuronal nicotinic acetylcholine receptors expressed in Xenopus oocytes.
Papke RL; Wecker L; Stitzel JA
J Pharmacol Exp Ther; 2010 May; 333(2):501-18. PubMed ID: 20100906
[TBL] [Abstract][Full Text] [Related]
16. Pharmacological and molecular studies on the interaction of varenicline with different nicotinic acetylcholine receptor subtypes. Potential mechanism underlying partial agonism at human α4β2 and α3β4 subtypes.
Arias HR; Feuerbach D; Targowska-Duda K; Kaczor AA; Poso A; Jozwiak K
Biochim Biophys Acta; 2015 Feb; 1848(2):731-41. PubMed ID: 25475645
[TBL] [Abstract][Full Text] [Related]
17. 5-Fluorotryptamine is a partial agonist at 5-HT3 receptors, and reveals that size and electronegativity at the 5 position of tryptamine are critical for efficient receptor function.
Bower KS; Price KL; Sturdee LE; Dayrell M; Dougherty DA; Lummis SC
Eur J Pharmacol; 2008 Feb; 580(3):291-7. PubMed ID: 18082160
[TBL] [Abstract][Full Text] [Related]
18. PSAB-OFP, a selective alpha 7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor.
Broad LM; Felthouse C; Zwart R; McPhie GI; Pearson KH; Craig PJ; Wallace L; Broadmore RJ; Boot JR; Keenan M; Baker SR; Sher E
Eur J Pharmacol; 2002 Oct; 452(2):137-44. PubMed ID: 12354563
[TBL] [Abstract][Full Text] [Related]
19. Varenicline has antidepressant-like activity in the forced swim test and augments sertraline's effect.
Rollema H; Guanowsky V; Mineur YS; Shrikhande A; Coe JW; Seymour PA; Picciotto MR
Eur J Pharmacol; 2009 Mar; 605(1-3):114-6. PubMed ID: 19168054
[TBL] [Abstract][Full Text] [Related]
20. Delineation of the functional properties and the mechanism of action of TMPPAA, an allosteric agonist and positive allosteric modulator of 5-HT3 receptors.
Gasiorek A; Trattnig SM; Ahring PK; Kristiansen U; Frølund B; Frederiksen K; Jensen AA
Biochem Pharmacol; 2016 Jun; 110-111():92-108. PubMed ID: 27086281
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
